Ionis Pharmaceuticals (IONS) Competitors $41.82 -0.87 (-2.04%) Closing price 04:00 PM EasternExtended Trading$41.60 -0.23 (-0.54%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, MDGL, EXAS, HALO, and RGENShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Is BIIB or IONS more profitable? Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Ionis Pharmaceuticals -28.25%-45.29%-8.99% Do analysts recommend BIIB or IONS? Biogen currently has a consensus target price of $185.74, suggesting a potential upside of 36.21%. Ionis Pharmaceuticals has a consensus target price of $60.92, suggesting a potential upside of 45.68%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Ionis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has preferable earnings and valuation, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$10.00B2.00$1.63B$10.4613.04Ionis Pharmaceuticals$705M9.45-$453.90M-$1.84-22.73 Does the media refer more to BIIB or IONS? In the previous week, Biogen had 13 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 47 mentions for Biogen and 34 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 1.16 beat Ionis Pharmaceuticals' score of 0.75 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 27 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of BIIB or IONS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, BIIB or IONS? Biogen has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. SummaryBiogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.67B$2.78B$5.76B$9.72BDividend YieldN/A1.67%4.40%4.10%P/E Ratio-22.7322.2230.1925.84Price / Sales9.45748.28474.17122.81Price / CashN/A26.0925.7828.79Price / Book11.215.529.425.99Net Income-$453.90M$31.83M$3.27B$265.29M7 Day Performance-3.71%1.09%2.04%2.53%1 Month Performance-0.99%0.83%3.58%0.92%1 Year Performance-10.87%6.98%30.08%18.70% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.5549 of 5 stars$41.82-2.0%$60.92+45.7%-9.0%$6.67B$705M-22.731,069Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.8376 of 5 stars$135.91-1.9%$185.74+36.7%-32.0%$19.93B$9.68B12.997,605Trending NewsINCYIncyte4.7151 of 5 stars$84.92-2.3%$81.20-4.4%+32.6%$16.58B$4.24B19.302,617Analyst ForecastUTHRUnited Therapeutics4.924 of 5 stars$314.10+0.3%$382.00+21.6%-10.3%$14.17B$2.88B12.261,305Positive NewsInsider TradeAnalyst RevisionNBIXNeurocrine Biosciences4.8571 of 5 stars$133.14+0.2%$160.90+20.9%-11.4%$13.20B$2.36B39.391,800Positive NewsBMRNBioMarin Pharmaceutical4.9955 of 5 stars$57.44-0.2%$93.17+62.2%-34.9%$11.03B$2.85B17.043,040Positive NewsEXELExelixis4.9068 of 5 stars$37.76-1.4%$44.06+16.7%+49.3%$10.16B$2.17B18.151,147MDGLMadrigal Pharmaceuticals3.3923 of 5 stars$391.43+5.8%$439.71+12.3%+64.1%$8.69B$180.13M-30.4690High Trading VolumeEXASExact Sciences4.9307 of 5 stars$45.09-1.1%$67.43+49.5%-20.5%$8.54B$2.76B-8.307,000Positive NewsHALOHalozyme Therapeutics4.6873 of 5 stars$68.96+2.5%$67.11-2.7%+14.5%$8.07B$1.02B15.78390Positive NewsRGENRepligen4.8534 of 5 stars$124.08-0.2%$169.45+36.6%-15.0%$6.98B$673.96M-496.301,778Positive News Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors BMRN Competitors EXEL Competitors MDGL Competitors EXAS Competitors HALO Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access